The Matrix therapy
restructures and protects the corneal tissue
CACICOL® , RGTA (REGENERATING AGENTS)
is a new alternative in a clinical context of chronic corneal disorders such as persistent epithelial defects and neurotrophic ulcers.
The RGTA-based technology in
CACICOL®
, also named
MATRIX THERAPY
, introduces a new therapeutic approach which aims at preserving the extracellular matrix, i.e. the cell environment.
RGTA®
replaces /mimics endogenous GAGs ( such as heparan sulfate) that have been degraded by enzymes. Their binding to matrix proteins (collagen, elastin, fibronectin,..) results in a mechanical protection against degradation. Restoration of extracellular matrix scaffolding properties is then induced, and so is the communication between cells.
These effects allow the re-creation of a suitable micro-environment for cells to respond properly to the cascade of signals needed for the normal tissue regeneration process to take place.
CACICOL®
(Poly (carboxymethylglucose sulfate) promotes a clear improvement of corneal healing, objectivised by a decrease in the ulcerated ocular surface or complete tissue regeneration.
> For more information on how to get CACICOL®, please contact your local Théa representatives <